Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
32.43
+0.43 (1.34%)
At close: Apr 28, 2025, 4:00 PM
31.94
-0.49 (-1.51%)
Pre-market: Apr 29, 2025, 5:49 AM EDT
Zai Lab Revenue
In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth. Zai Lab had revenue of $109.07M in the quarter ending December 31, 2024, with 65.68% growth.
Revenue (ttm)
$398.99M
Revenue Growth
+49.59%
P/S Ratio
8.04
Revenue / Employee
$213,477
Employees
1,869
Market Cap
3.56B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ZLAB News
- 3 days ago - Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025 - Business Wire
- 5 days ago - Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting - Business Wire
- 7 days ago - Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors - Business Wire
- 4 weeks ago - Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting - Business Wire
- 5 weeks ago - Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth - Seeking Alpha
- 5 weeks ago - Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks - Seeking Alpha
- 6 weeks ago - Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
- 2 months ago - Zai Lab Announces Participation in Investor Conferences in March 2025 - Business Wire